Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of FMO3 polymorphisms on sulindac pharmacokinetics in healthy Chinese male volunteers
ChiCTR-OCS-14004090Phase 4Completed
- Sponsor
- Pharmacogenetics Research Institute, Xiangya Hospital, Central South University
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sulindac, sponsored by Pharmacogenetics Research Institute, Xiangya Hospital, Central South University. Primary endpoint: Plasma concentration. Started Apr 2013; status: completed.
02
Drugs
sulindac
Beyond the preview
Go deeper on ChiCTR-OCS-14004090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCS-14004090.